Adam S. Dayoub

Recruited to lead operational stabilization and process modernization within a highly regulated defense and aerospace technology environment Directed facilities and operations teams, aligning infrastructure, compliance, and production readiness with organizational objectives Led complex capital and infrastructure projects, including laboratory spaces, specialized equipment installations, and construction initiatives Served as primary liaison between engineering, manufacturing, executive leadership, and external stakeholders to ensure cross-functional alignment Designed and implemented enterprise reporting systems, standardized coding frameworks, and operational workflows where no prior infrastructure existed Established de novo governance, documentation, and process controls to improve transparency, accountability, and regulatory readiness Managed relationships with utility providers, commercial vendors, and technology partners to support mission-critical operations Delivered measurable improvements in operational efficiency, risk mitigation, and project execution timelines

Directed multi-asset pipeline programs, overseeing project management, timelines, and cross-functional deliverables from early development through clinical readiness Led scientific positioning, investor diligence, and external engagement, translating complex drug design and development strategies for financial partners, executive stakeholders, and international audiences Provided senior leadership in organizational development, operational problem-solving, and culture-building to support sustainable growth and high-performance teams Conducted rigorous scientific and asset evaluations, identifying data quality risks, methodological gaps, and development liabilities to support informed investment and portfolio decisions Designed and supported clinical development strategies, including biomarker identification and endpoint selection for early- and mid-phase clinical trials

Led translational and clinical development programs across immunology, oncology, and neonatal disease Achieved FDA Fast-Track designation for two investigational assets Directed IND submissions and regulatory communications with FDA and EMA Served as primary scientific communicator to investors, partners, and regulators Coordinated clinical design and execution with 15+ CROs and 10+ industry sponsors Built strong collaborative relationships across academic, industry, and regulatory teams Established partnership with Johnson & Johnson Blue Knights Lab Supported venture capital due diligence and $100M+ asset valuation Delivered scientific presentations at ARVO, PAS, ACS, and industry forums Authored peer-reviewed publications and contributed to patent development

Developed monoclonal antibody assays supporting biotech acquisition activity Led translational research for oncology therapeutic programs Served as liaison between academic researchers and industry partners Communicated complex biomarker and clinical data to multidisciplinary teams Collaborated with Eli Lilly, Peregrine, Oncologie, and Tuevol Supported four clinical trials with translational and clinical insights Published seven peer-reviewed manuscripts and presented at major conferences